Hemolytic Uremic Syndrome

Emmanuel J Favaloro

doi:10.1055/s-0030-1262878

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2010; 36(6): 573-574
DOI: 10.1055/s-0030-1262878

PREFACE

Hemolytic Uremic Syndrome

Emmanuel J. Favaloro¹

¹Department of Haematology, ICPMR, Westmead Hospital, Westmead, NSW, Australia

Abstract

Full Text

References

REFERENCES

1 Franchini M, Montagnana M, Targher G, Lippi G. Reduced von Willebrand factor-cleaving protease levels in secondary thrombotic microangiopathies and other diseases. Semin Thromb Hemost. 2007; 33(8) 787-797
2 Zhou Z, Nguyen T C, Guchhait P, Dong J F. Von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura. Semin Thromb Hemost. 2010; 36(1) 71-81
3 Mammen E F. Thrombotic microangiopathies. Semin Thromb Hemost. 2006; 32(2) 79-80
4 Prüfer F, Scheiring J, Sautter S et al.. Terminal complement complex (C5b-9) in children with recurrent hemolytic uremic syndrome. Semin Thromb Hemost. 2006; 32(2) 121-127
5 Gordjani N, Sutor A H, Zimmerhackl L B, Brandis M. Hemolytic uremic syndromes in childhood. Semin Thromb Hemost. 1997; 23(3) 281-293
6 Sutor A H, Thomas K B, Prüfer F H, Grohmann A, Brandis M, Zimmerhackl L B. Function of von Willebrand factor in children with diarrhea-associated hemolytic-uremic syndrome (D + HUS). Semin Thromb Hemost. 2001; 27(3) 287-292
7 Karch H, Friedrich A W, Gerber A, Zimmerhackl L B, Schmidt M A, Bielaszewska M. New aspects in the pathogenesis of enteropathic hemolytic uremic syndrome. Semin Thromb Hemost. 2006; 32(2) 105-112
8 Zimmerhackl L B, Besbas N, Jungraithmayr T European Study Group for Haemolytic Uraemic Syndromes and Related Disorders et al. Epidemiology, clinical presentation, and pathophysiology of atypical and recurrent hemolytic uremic syndrome. Semin Thromb Hemost. 2006; 32(2) 113-120
9 Karpman D, Sartz L, Johnson S. Pathophysiology of typical hemolytic uremic syndrome. Semin Thromb Hemost. 2010; 36(6) 575-585
10 Zimmerhackl L-B, Rosales A, Hofer J et al.. Enterohemorrhagic Escherichia coli O26:H11-associated hemolytic uremic syndrome: bacteriology and clinical presentation. Semin Thromb Hemost. 2010; 36(6) 586-593
11 Bitzan M, Schaefer F, Reymond D. Treatment of typical (enteropathic) hemolytic uremic syndrome. Semin Thromb Hemost. 2010; 36(6) 594-610
12 Oppermann M, Würzner R. Modern determination of complement activation. Semin Thromb Hemost. 2010; 36(6) 611-619
13 Orth D, Würzner R. Complement in typical HUS. Semin Thromb Hemost. 2010; 36(6) 620-624
14 Skerka C, Zipfel P F, Müller D et al.. The autoimmune disease DEAP HUS (hemolytic uremic syndrome). Semin Thromb Hemost. 2010; 36(6) 625-632
15 Dragon-Durey M-A, Blanc C, Garnier A, Hofer J, Vester U, Zimmerhackl L-B. Anti-factor H auto-antibodies associated hemolytic uremic syndrome: review of literature of the auto-immune form of HUS. Semin Thromb Hemost. 2010; 36(6) 633-640
16 Moglie L Q, Roumenina L, Noris M, Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome associated with mutations in complement regulator genes. Semin Thromb Hemost. 2010; 36(6) 641-652
17 Kavanagh D, Richards A, Goodship T, Jalanko H. Transplantation in atypical hemolytic uremic syndrome. Semin Thromb Hemost. 2010; 36(6) 653-659
18 Emlen W, Li W, Kirschfink M. Therapeutic complement inhibition: new developments. Semin Thromb Hemost. 2010; 36(6) 660-668
19 Köse Ö, Jungraithmayr T, Zimmerhackl L-B, Mache C, Nürnberger J. New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab. Semin Thromb Hemost. 2010; 36(6) 669-672
20 Loirat C, Garnier A, Sellier-Leclerc A-L, Kwon T. Plasmatherapy in atypical hemolytic uremic syndrome. Semin Thromb Hemost. 2010; 36(6) 673-681